Daria O. Koshkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daria O. Koshkina has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alexey Valeryevich Feofanov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia
9 shared publications - Natalya V. Maluchenko
Lomonosov Moscow State University
9 shared publications - Vasily M. Studitsky
Department of Biology, Lomonosov Moscow State University, Moscow, Russia
7 shared publications - Anna N. Korovina
Lomonosov Moscow State University
4 shared publications - A. A. Lobanova
Lomonosov Moscow State University
2 shared publications - Dmitry Nilov
Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Moscow, Russia
2 shared publications
Latest Publications
- 1 December 2025
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 80 (S1) , S64-S70
Ni-NTA Bead-Based Real-Time Monitoring of PARPs Inhibitor Binding
- 1 December 2025
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 80 (S1) , S64-S70
Ni-NTA Bead-Based Real-Time Monitoring of PARPs Inhibitor Binding
- 1 December 2025
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 80 (S1) , S59-S63
PARP1-Dependent Alterations in Nucleosome Organization: Potential Involvement of p53
Chromatin of eukaryotic organisms is a complexly organized and dynamic complex. Chromatin proteins provide proper regulation of gene expression, DNA replic
- 1 December 2025
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 80 (S1) , S59-S63
PARP1-Dependent Alterations in Nucleosome Organization: Potential Involvement of p53
Chromatin of eukaryotic organisms is a complexly organized and dynamic complex. Chromatin proteins provide proper regulation of gene expression, DNA replic
- Open Access
Non-Classical H1-like PARP1 Binding to Chromatosome
Poly(ADP-ribose)polymerase 1 (PARP1) is an enzyme that interacts with chromatin during DNA repair and transcription processes; the molecular mechanisms of these processes remain to be determined. Previously, we have shown that PARP1 can bind to and reorganize nucleosomes using two modes of interaction with a mono-nucleosome, which are realized through PARP1 binding to the ends of linker DNA and to the nucleosome core. Here, it is shown that the latter mode of binding induces the reorganization of nucleosome structure and is more stable under the conditions of poly(ADP-ribosyl)ation (PARylation). The initial nucleosome structure is fully recovered after the dissociation of autoPARylated PARP1. The competition between PARP1 and linker histone H1.0 for binding to a nucleosome is mediated by the PARP1-H1.0 interaction and is affected by the length of linker DNA fragments. Longer linkers stabilize H1.0-nucleosome complexes, while shorter linkers facilitate displacement of H1.0 from the chromatosome by PARP1. PARylation removes both H1.0 and PARP1 from the complexes with nucleosomes. The data suggest that the H1.0 displacement from chromatin by PARP1 that is likely modulated by the density of nucleosomes might reduce chromatin compaction and facilitate access of PARP1-dependent DNA repair and transcription factors to nucleosome and inter-nucleosomal DNA.
Open AccessNon-Classical H1-like PARP1 Binding to Chromatosome
Poly(ADP-ribose)polymerase 1 (PARP1) is an enzyme that interacts with chromatin during DNA repair and transcription processes; the molecular mechanisms of these processes remain to be determined. Previously, we have shown that PARP1 can bind to and reorganize nucleosomes using two modes of interaction with a mono-nucleosome, which are realized through PARP1 binding to the ends of linker DNA and to the nucleosome core. Here, it is shown that the latter mode of binding induces the reorganization of nucleosome structure and is more stable under the conditions of poly(ADP-ribosyl)ation (PARylation). The initial nucleosome structure is fully recovered after the dissociation of autoPARylated PARP1. The competition between PARP1 and linker histone H1.0 for binding to a nucleosome is mediated by the PARP1-H1.0 interaction and is affected by the length of linker DNA fragments. Longer linkers stabilize H1.0-nucleosome complexes, while shorter linkers facilitate displacement of H1.0 from the chromatosome by PARP1. PARylation removes both H1.0 and PARP1 from the complexes with nucleosomes. The data suggest that the H1.0 displacement from chromatin by PARP1 that is likely modulated by the density of nucleosomes might reduce chromatin compaction and facilitate access of PARP1-dependent DNA repair and transcription factors to nucleosome and inter-nucleosomal DNA.
- 1 January 2025
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 80 (№3S, 2025) , 73-80
Ni-NTA bead-based real-time monitoring of PARPs inhibitor binding
This study establishes a real-time fluorescence microscopy platform for visualizing ligand binding dynamics to His-tagged proteins bound to Ni-NTA agarose beads. By preserving solution-phase kinetics while enabling sub-minute temporal resolution in physiological buffers, the methodology overcomes critical limitations of surface-based techniques and gel electrophoretic methods. We applied this platform to investigate inhibitor action within a nucleosomal system, a more physiologically relevant context than free DNA. Through studies of PARP2-nucleosome interactions modulated by clinical inhibitors (talazoparib, veliparib) and by reaction of poly(ADP-ribosyl)ation in the presence of NAD+, we demonstrate direct spatial and temporal resolution of chromatin-protein dynamics. The platform’s virtually unlimited buffer compatibility, real-time monitoring capabilities, and elimination of covalent immobilization artifacts provide transformative insights into drug mechanisms and chromatin engagement processes.
- 1 January 2025
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 80 (№3S, 2025) , 73-80
Ni-NTA bead-based real-time monitoring of PARPs inhibitor binding
This study establishes a real-time fluorescence microscopy platform for visualizing ligand binding dynamics to His-tagged proteins bound to Ni-NTA agarose beads. By preserving solution-phase kinetics while enabling sub-minute temporal resolution in physiological buffers, the methodology overcomes critical limitations of surface-based techniques and gel electrophoretic methods. We applied this platform to investigate inhibitor action within a nucleosomal system, a more physiologically relevant context than free DNA. Through studies of PARP2-nucleosome interactions modulated by clinical inhibitors (talazoparib, veliparib) and by reaction of poly(ADP-ribosyl)ation in the presence of NAD+, we demonstrate direct spatial and temporal resolution of chromatin-protein dynamics. The platform’s virtually unlimited buffer compatibility, real-time monitoring capabilities, and elimination of covalent immobilization artifacts provide transformative insights into drug mechanisms and chromatin engagement processes.
- 1 January 2025
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 80 (№3S, 2025) , 67-72
PARP1-dependent alterations in nucleosome organization: potential involvement of p53
Chromatin of eukaryotic organisms is a complexly organized and dynamic complex. Chromatin proteins provide proper regulation of gene expression, DNA replication, and DNA repair. Among the most important regulators of chromatin architecture among non-histone proteins are p53 and PARP1, which are involved in the cellular response to DNA damage. In the present study, we investigated the cooperative and competitive binding of the DNA-binding domain (DBD) of p53 and the enzyme PARP1 to mononucleosomes reconstituted on the Widom 603 sequence with an embedded p53 binding site. To detect interactions, the electrophoretic mobility shift assay (EMSA) method with fluorescently labeled DNA. Complexes were formed in two ways: nucleosomes were pre-incubated with p53 DBD and then PARP1 was added, or the nucleosome-PARP1 complex was formed first and then p53 DBD was introduced. The results showed that the order of protein addition determines the nature of their interaction with the nucleosome: at low p53 concentrations, displacement of this protein by PARP1 is observed, while at higher p53 concentrations, stable nucleosome-p53 complexes are formed, undisturbed by PARP1. No stable ternary nucleosome-p53-PARP1 complexes were detected.
- 1 January 2025
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 80 (№3S, 2025) , 67-72
PARP1-dependent alterations in nucleosome organization: potential involvement of p53
Chromatin of eukaryotic organisms is a complexly organized and dynamic complex. Chromatin proteins provide proper regulation of gene expression, DNA replication, and DNA repair. Among the most important regulators of chromatin architecture among non-histone proteins are p53 and PARP1, which are involved in the cellular response to DNA damage. In the present study, we investigated the cooperative and competitive binding of the DNA-binding domain (DBD) of p53 and the enzyme PARP1 to mononucleosomes reconstituted on the Widom 603 sequence with an embedded p53 binding site. To detect interactions, the electrophoretic mobility shift assay (EMSA) method with fluorescently labeled DNA. Complexes were formed in two ways: nucleosomes were pre-incubated with p53 DBD and then PARP1 was added, or the nucleosome-PARP1 complex was formed first and then p53 DBD was introduced. The results showed that the order of protein addition determines the nature of their interaction with the nucleosome: at low p53 concentrations, displacement of this protein by PARP1 is observed, while at higher p53 concentrations, stable nucleosome-p53 complexes are formed, undisturbed by PARP1. No stable ternary nucleosome-p53-PARP1 complexes were detected.
- Open Access
- 2 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (11) , 1398
Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1
The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the catalytic activity of PARP1 was studied using Western blotting, spectrophotometry, electrophoretic mobility shift assay, and single particle Förster resonance energy transfer microscopy. Resveratrol inhibited PARP1 activity at micro- and sub-micromolar concentrations, but the inhibitory effect decreased at higher concentrations due to the aggregation of the polyphenol. The inhibition of PARP1 by resveratrol was accompanied by its binding to the enzyme catalytic center and a subsequent decrease in PARP1 affinity to nucleosomal DNA. Concurrent binding of talazoparib to the substrate binding pocket of PARP1, which occurs in the presence of resveratrol, restores the interaction of PARP1 with nucleosomes, suggesting that the binding sites of resveratrol and talazoparib overlap. The data suggest that resveratrol can be classified as a natural inhibitor of PARP1.
- 2 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (11) , 1398
Open AccessResveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1
The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the catalytic activity of PARP1 was studied using Western blotting, spectrophotometry, electrophoretic mobility shift assay, and single particle Förster resonance energy transfer microscopy. Resveratrol inhibited PARP1 activity at micro- and sub-micromolar concentrations, but the inhibitory effect decreased at higher concentrations due to the aggregation of the polyphenol. The inhibition of PARP1 by resveratrol was accompanied by its binding to the enzyme catalytic center and a subsequent decrease in PARP1 affinity to nucleosomal DNA. Concurrent binding of talazoparib to the substrate binding pocket of PARP1, which occurs in the presence of resveratrol, restores the interaction of PARP1 with nucleosomes, suggesting that the binding sites of resveratrol and talazoparib overlap. The data suggest that resveratrol can be classified as a natural inhibitor of PARP1.
- Open Access
- 1 January 2024
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 79 (№4, 2024) , 322-329
Gel electrophoretic analysis of protein-DNA complexes to classify inhibitors of poly(ADP-ribose) polymerases 1 and 2
Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2) play an important role in repairing DNA, and their inhibition is being used to treat certain oncological diseases. New inhibitors of PARP are being actively developed and the mechanisms of their action are being studied. In the present work, using the inhibitors talazoparib, olaparib and veliparib, as example, it is shown that electrophoresis of DNA complexes with PARP1 and PARP2 in polyacrylamide gel in the presence of inhibitors makes it possible to identify the effect of inhibitors on the affinity of enzymes to DNA, and after adding the NAD+ substrate, to evaluate the inhibition of the catalytic activity of enzymes. When selecting new inhibitors for biomedical research, it is important to consider these mechanisms of action against PARP1 and PARP2.
- 1 January 2024
- Published by Moscow University Press in Vestnik Moskovskogo universiteta. Seria 16. Biologia
- Vol. 79 (№4, 2024) , 322-329
Open AccessGel electrophoretic analysis of protein-DNA complexes to classify inhibitors of poly(ADP-ribose) polymerases 1 and 2
Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2) play an important role in repairing DNA, and their inhibition is being used to treat certain oncological diseases. New inhibitors of PARP are being actively developed and the mechanisms of their action are being studied. In the present work, using the inhibitors talazoparib, olaparib and veliparib, as example, it is shown that electrophoresis of DNA complexes with PARP1 and PARP2 in polyacrylamide gel in the presence of inhibitors makes it possible to identify the effect of inhibitors on the affinity of enzymes to DNA, and after adding the NAD+ substrate, to evaluate the inhibition of the catalytic activity of enzymes. When selecting new inhibitors for biomedical research, it is important to consider these mechanisms of action against PARP1 and PARP2.
- Open Access
Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin. Previous studies have demonstrated the PARPi-induced trapping of PARP1 on DNA, although details of the mechanism remain controversial. Here, the interactions of PARP1-nucleosome complexes with PARPi, olaparib (Ola), talazoparib (Tala), and veliparib (Veli) were studied. PARPi trap PARP1 on nucleosomes without affecting the structure of PARP1-nucleosome complexes. The efficiency of PARP1 trapping on nucleosomes increases in the order of Tala>Ola>>Veli, recapitulating the relative trapping efficiencies of PARPi in cells, but different from the relative potency of PARPi to inhibit the catalytic activity of PARP1. The efficiency of PARP1 trapping on nucleosomes correlates with the level of inhibition of auto-PARylation, which otherwise promotes the dissociation of PARP1-nucleosome complexes. The trapping efficiencies of Tala and Ola (but not Veli) are additionally modulated by the enhanced PARP1 binding to nucleosomes. The dissociation of PARP1-nucleosome complexes occurs without a loss of histones and leads to the restoration of the intact structure of nucleosomal DNA. The data suggest that the chromatin structure can considerably affect the efficiency of the PARPi action.
Open AccessInteractions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin. Previous studies have demonstrated the PARPi-induced trapping of PARP1 on DNA, although details of the mechanism remain controversial. Here, the interactions of PARP1-nucleosome complexes with PARPi, olaparib (Ola), talazoparib (Tala), and veliparib (Veli) were studied. PARPi trap PARP1 on nucleosomes without affecting the structure of PARP1-nucleosome complexes. The efficiency of PARP1 trapping on nucleosomes increases in the order of Tala>Ola>>Veli, recapitulating the relative trapping efficiencies of PARPi in cells, but different from the relative potency of PARPi to inhibit the catalytic activity of PARP1. The efficiency of PARP1 trapping on nucleosomes correlates with the level of inhibition of auto-PARylation, which otherwise promotes the dissociation of PARP1-nucleosome complexes. The trapping efficiencies of Tala and Ola (but not Veli) are additionally modulated by the enhanced PARP1 binding to nucleosomes. The dissociation of PARP1-nucleosome complexes occurs without a loss of histones and leads to the restoration of the intact structure of nucleosomal DNA. The data suggest that the chromatin structure can considerably affect the efficiency of the PARPi action.
- Open Access
- 15 June 2021
- Published by Acta Naturae Ltd in Acta Naturae
- Vol. 13 (2) , 58-69
Poly(ADP-Ribosyl) Code Functions
Poly(ADP-ribosyl)ation plays a key role in cellular metabolism. Covalent poly(ADP-ribosyl)ation affects the activity of the proteins engaged in DNA repair, chromatin structure regulation, gene expression, RNA processing, ribosome biogenesis, and protein translation. Non-covalent PAR-dependent interactions are involved in the various types of cellular response to stress and viral infection, such as inflammation, hormonal signaling, and the immune response. The review discusses how structurally different poly(ADP-ribose) (PAR) molecules composed of identical monomers can differentially participate in various cellular processes acting as the so-called PAR code. The article describes the ability of PAR polymers to form functional biomolecular clusters through a phase-separation in response to various signals. This phase-separation contributes to rapid spatial segregation of biochemical processes and effective recruitment of the necessary components. The cellular PAR level is tightly controlled by a network of regulatory proteins: PAR code writers, readers, and erasers. Impaired PAR metabolism is associated with the development of pathological processes causing oncological, cardiovascular, and neurodegenerative diseases. Pharmacological correction of the PAR level may represent a new approach to the treatment of various diseases.
- 15 June 2021
- Published by Acta Naturae Ltd in Acta Naturae
- Vol. 13 (2) , 58-69
Open AccessPoly(ADP-Ribosyl) Code Functions
Poly(ADP-ribosyl)ation plays a key role in cellular metabolism. Covalent poly(ADP-ribosyl)ation affects the activity of the proteins engaged in DNA repair, chromatin structure regulation, gene expression, RNA processing, ribosome biogenesis, and protein translation. Non-covalent PAR-dependent interactions are involved in the various types of cellular response to stress and viral infection, such as inflammation, hormonal signaling, and the immune response. The review discusses how structurally different poly(ADP-ribose) (PAR) molecules composed of identical monomers can differentially participate in various cellular processes acting as the so-called PAR code. The article describes the ability of PAR polymers to form functional biomolecular clusters through a phase-separation in response to various signals. This phase-separation contributes to rapid spatial segregation of biochemical processes and effective recruitment of the necessary components. The cellular PAR level is tightly controlled by a network of regulatory proteins: PAR code writers, readers, and erasers. Impaired PAR metabolism is associated with the development of pathological processes causing oncological, cardiovascular, and neurodegenerative diseases. Pharmacological correction of the PAR level may represent a new approach to the treatment of various diseases.